Wave Life Sciences, Inc. revenue
Wave Life Sciences, Inc.'s revenue was $42.7m in fiscal 2025, down 60.5% on the year before. Since fiscal 2015 ($152,000) it has grown at a compound 75.7% a year. Over the last twelve months it was $70.9m.
Revenue history
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 4 | 14 | 16 | 20 | 41 | 4 | 113 | 108 | 43 | 71 |
| Growth on the year before | — | +877.0% | +149.4% | +289.1% | +10.9% | +25.6% | +104.0% | −91.1% | +>999% | −4.4% | −60.5% | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Wave Life Sciences, Inc. | $70.9m | 202.3% | 20.7% |
| Viridian Therapeutics, Inc.\de | $71.1m | 23220.3% | 264.4% |
| Compugen LTD | $72.8m | 161.1% | 302.6% |
| Recursion Pharmaceuticals, Inc. | $68.2m | 56.2% | 12.9% |
| Cytokinetics Inc | $67.7m | -21.1% | 89.5% |
| Assembly Biosciences, Inc. | $74.8m | 125.1% | -3.3% |
Compare with peers
- Viridian Therapeutics, Inc.\de revenue
- Compugen LTD revenue
- Recursion Pharmaceuticals, Inc. revenue
- Cytokinetics Inc revenue
- Assembly Biosciences, Inc. revenue
Head to head: VRDN vs WVECGEN vs WVERXRX vs WVECYTK vs WVE
More: Biotechnology stocks compared, Health Care sector, rankings of US companies